|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-6-26
|
|
pubmed:abstractText |
This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex').
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androstenedione,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor Modulators,
http://linkedlifedata.com/resource/pubmed/chemical/Megestrol Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/anastrozole,
http://linkedlifedata.com/resource/pubmed/chemical/formestane,
http://linkedlifedata.com/resource/pubmed/chemical/fulvestrant,
http://linkedlifedata.com/resource/pubmed/chemical/letrozole
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0167-6806
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
207-11
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12825855-Adult,
pubmed-meshheading:12825855-Aged,
pubmed-meshheading:12825855-Aged, 80 and over,
pubmed-meshheading:12825855-Androstenedione,
pubmed-meshheading:12825855-Antineoplastic Agents, Hormonal,
pubmed-meshheading:12825855-Aromatase Inhibitors,
pubmed-meshheading:12825855-Breast Neoplasms,
pubmed-meshheading:12825855-Disease Progression,
pubmed-meshheading:12825855-Double-Blind Method,
pubmed-meshheading:12825855-Down-Regulation,
pubmed-meshheading:12825855-Drug Resistance, Neoplasm,
pubmed-meshheading:12825855-Enzyme Inhibitors,
pubmed-meshheading:12825855-Estradiol,
pubmed-meshheading:12825855-Estrogen Receptor Modulators,
pubmed-meshheading:12825855-Female,
pubmed-meshheading:12825855-Follow-Up Studies,
pubmed-meshheading:12825855-Humans,
pubmed-meshheading:12825855-Megestrol Acetate,
pubmed-meshheading:12825855-Middle Aged,
pubmed-meshheading:12825855-Nitriles,
pubmed-meshheading:12825855-Postmenopause,
pubmed-meshheading:12825855-Retrospective Studies,
pubmed-meshheading:12825855-Salvage Therapy,
pubmed-meshheading:12825855-Treatment Outcome,
pubmed-meshheading:12825855-Triazoles
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
|
|
pubmed:affiliation |
Department of Gynecologic Oncology, University Hospitals, Leuven, Belgium. Ignace.Vergote@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
